Innate Immune Responses in Chronic Obstructive Pulmonary Disease (COPD) Patients

Mahidol University20 enrolled

Overview

We hypothesize that ongoing and more severe airway inflammation in COPD may result from the impairment in activation of innate immune response

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Chronic Obstructive Pulmonary Disease

Interventions

BudesonideDRUG

Inhaled budesonide 400 mcg twice a day for 2 weeks

Eligibility

Sex: ALLMin age: 18 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: * clinical diagnosis of COPD or asthma * a ratio of prebronchodilator FEV1 to forced vital capacity (FVC) equal to or less than 0.70 * postbronchodilator FEV1 \> or = 50% predicted Exclusion Criteria: * Exacerbation * systemic corticosteroids * DM, HIV and autoimmune disease * immunosuppressive therapy

Locations (1)

Kittipong Maneechotesuwan

Bangkoknoi, BKK, Thailand

Outcomes

Primary Outcomes

Sputum IL-8, IL-17

Time frame: 2 WEEKS

Secondary Outcomes

The expression of NF-kappa B in sputum macrophages

Time frame: 2 WEEKS

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.